Polyclinic III

May 3, 2023 | frontiersin.org | Vrije Universiteit Brussels |hospitals Leuven |Polyclinic III |Justus Liebig

Post-hoc analysis of a randomized, double blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders Valeria Sordi1 , Paolo Monti1 , Vito Lampasona1 , Raffaella Melzi1, Silvia Pellegrini1, Bart Keymeulen2, 3, Pieter Gillard4, Thomas Linn5 , Emanuele Bosi1, 6, Ludger Rose7, Paolo Pozzilli8 , Francesco Giorgino9 , Efisio Cossu10 and Lorenzo Piemonti1, 6* 1Diabetes Research Institute, San Raffaele...